Leukemia drug holiday: study finds many can stop imatinib without relapse
NCT ID NCT01343173
First seen May 21, 2026 · Last updated Jun 19, 2026 · Updated 4 times
Summary
This study looked at 220 adults with chronic myeloid leukemia who had been in deep remission for at least two years while taking imatinib. Researchers wanted to see if stopping the drug would cause the cancer to come back. They found that many patients stayed in remission after stopping, and they identified factors that help predict who can safely stop treatment without relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKAEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
C.H.U. Brabois
Vandœuvre-lès-Nancy, 54500, France
-
CH Annecy
Annecy, France
-
CH Bretagne Atlantique
Vannes, France
-
CH Régional de l'ILE DE LA REUNION/ Groupe Hospitalier Sud
Saint-Pierre, France
-
CH Sud Francilien
Corbeil-Essonnes, France
-
CH Valence
Valence, France
-
CH Yves Le Foll
Saint-Brieuc, France
-
CHR La Réunion
Saint-Denis, 97405, France
-
CHU Bensançon
Besançon, France
-
CHU Caen
Caen, France
-
CHU Dupuytren
Limoges, France
-
CHU Grenoble
Grenoble, 38043, France
-
CHU Hôtel-Dieu
Nantes, 44035, France
-
CHU de Nice - Hôpital Archet 1
Nice, 06202, France
-
Centre Henri Becquerel
Rouen, France
-
Centre Hospitalier - La Roche sur Yon
La Roche-sur-Yon, 85025, France
-
Centre Hospitalier de Nevers
Nevers, 58033, France
-
Centre Hospitalier de Versailles - Hôpital André Mignot
Versailles, 78157, France
-
Hôpital Edouard Herriot
Lyon, 69374, France
-
Hôpital Henri-Mondor
Créteil, 94000, France
-
Hôpital Morvan
Brest, 29285, France
-
Hôpital Necker-Enfants Malades
Paris, 75743, France
-
Hôpital Pontchaillou
Rennes, 35033, France
-
Hôpital Purpan
Toulouse, 31059, France
-
Hôpital Saint Louis
Paris, 75475, France
-
Hôpitaux civils de Colmar
Colmar, 68000, France
-
Institut Bergonié
Bordeaux, 33076, France
-
Institut Paoli Calmette
Marseille, 13273, France
-
Lille University hospital - Hôpital Claude Huriez
Lille, 59037, France
-
University Hospital Angers
Angers, 49033, France
-
University Hospital Bordeaux, Hôpital du Haut Lévêque
Pessac, 33604, France
-
University Hospital Poitiers - Hôpital Jean Bernard
Poitiers, 86021, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.